generation,stage,candidate_idx,risk_aversion,herd_behavior,profit_driven,ticker,company,id,quarter,date,permno,holding_t,y_true,pred,abs_error,reward,valid,best_k,profile_strength_mode,x_risk_mean,x_herd_mean,x_profit_mean,overall_mean,raw_output,reason,answer_body
91,llm_candidates,0,0.5499994500005501,0.24999975000025002,0.19999980000020004,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.","{""holding_log_delta"": -0.03}"
91,llm_candidates,1,0.44999955000045005,0.34999965000035,0.19999980000020004,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.","{""holding_log_delta"": -0.03}"
91,llm_candidates,2,0.49999950000050003,0.3999996000004001,0.09999990000010002,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.","{""holding_log_delta"": -0.03}"
91,llm_candidates,3,0.5999994000006,0.19999980000020004,0.19999980000020004,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.","{""holding_log_delta"": -0.03}"
91,llm_candidates,4,0.3999996000004001,0.44999955000045005,0.14999985000015,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's previous quarter volatility is moderately high (0.282), which could temper the magnitude of the increase due to risk management considerations. The fund's current holding is substantial relative to its AUM, suggesting limited room for large incremental changes, so any adjustment would likely be modest.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's previous quarter volatility is moderately high (0.282), which could temper the magnitude of the increase due to risk management considerations. The fund's current holding is substantial relative to its AUM, suggesting limited room for large incremental changes, so any adjustment would likely be modest.","{""holding_log_delta"": -0.03}"
91,llm_candidates,5,0.34999965000035,0.49999950000050003,0.14999985000015,VRTX,VERTEX PHARMACEUTICALS INC,210,NA,2017-07-01 00:00:00,76744,5118.977367,0.00491448745510791,-0.03,0.03491448745510791,-0.03491448745510791,True,1,type_mean,0.0083004769074155,0.0070097321687576,0.0811969348655934,0.03216904798058883,"
<think>Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.</think>
<answer>
{""holding_log_delta"": -0.03}
</answer>","Given the firm's high profitability (profit=0.176) and strong asset growth (Gat=0.169), alongside its elevated beta (1.681) indicating higher systematic risk, a growth-oriented investor might increase exposure to capture potential upside. However, the stock's high volatility (stock_vol_q_prev=0.282) and the fund's substantial AUM relative to the position size suggest caution, potentially limiting the magnitude of the increase. The current holding is already significant relative to the stock's S&P 500 weight, which may temper further allocation.","{""holding_log_delta"": -0.03}"
